Department of Clinical Laboratory, Beijing Shijitan Hospital, Capital Medical University, 10 Tieyi Road, Haidian District, Beijing, 100038, China.
Beijing Key Laboratory of Urinary Cellular Molecular Diagnostics, Beijing, China.
BMC Cancer. 2023 Mar 29;23(1):287. doi: 10.1186/s12885-023-10752-2.
Programmed death-1 (PD-1) and T cell immunoglobulin and mucin-domain-containing molecule 3(Tim-3) may be used as the biomarkers for the therapy in patients with peritoneal neoplasms. In the current study, the differential percentages of peripheral PD-1 and Tim-3 are explored to investigate whether to associate with primary sites and pathological types of patients with peritoneal neoplasms or not. We also investigated the frequencies of PD-1 and Tim-3 on circulating Lymphocytes, CD3 + T cells, CD3 + CD4 + T cells and CD3 + CD8 + T cells if would correlate with the progression-free survival of peritoneal neoplasms patients.
115 patients with peritoneal neoplasms were recruited, subjected to multicolor flow cytometric analyses of the percentages of PD-1 and Tim-3 receptors of circulating Lymphocytes, CD3 + T cells, CD3 + CD4 + T cells and CD3 + CD8 + T cells. The peritoneal neoplasms patients were divided into primary group and secondary group depending on whether the tumor had primary focus and limited to peritoneal tumor or not. Then all the patients were regrouped by the pathological types of neoplasms (adenocarcinoma, mesothelioma, and pseudomyxoma). The secondary peritoneal neoplasms group was divided into the different primary site groups (colon, gastric, gynecology). This study also enrolled 38 cases of normal volunteers. The above markers were explored by flow cytometer, to find the differential levels in peritoneal neoplasms patients compared with normal group in peripheral blood.
Higher levels of CD4 + T lymphocytes, CD8 + T lymphocytes, CD45 + PD-1 + lymphocytes, CD3 + PD-1 + T cells, CD3 + CD4 + PD-1 + T cells, CD3 + CD8 + PD-1 + T cells and CD45 + Tim-3 + lymphocytes were found in peritoneal neoplasms group than normal control (the p value was respectively 0.004, 0.047, 0.046, 0.044, 0.014, 0.038 and 0.017). Compared with primary peritoneal neoplasms group, the percentages of CD45 + PD-1 + lymphocytes, CD3 + PD-1 + T cells, and CD3 + CD4 + PD-1 + T cells were increased in the secondary peritoneal neoplasms group (the p value was respectively 0.010, 0.044, and 0.040), while PD-1 did not correlate with the primary sites in secondary group (P > 0.05). Tim-3 had no statistical differences in primary peritoneal neoplasms group compared with secondary group (p > 0.05), but CD45 + Tim-3+% lymphocytes, CD3 + Tim-3+%T cells, and CD3 + CD4 + Tim-3 + T cells were associated with different secondary sites of peritoneal neoplasms (p < 0.05). In the different pathological type groups, the percentages of CD45 + PD-1 + lymphocytes, CD3 + PD-1 + T cells presented the higher levels in adenocarcinoma group compared with mesothelioma group (p = 0.048, p = 0.045). The frequencies of CD45 + PD-1 + lymphocytes and CD3 + PD-1 + T cells in peripheral blood were associated with progression-free survival (PFS).
Our work uncovers peripheral PD-1 and Tim-3 percentages are associated with primary sites and pathological types of peritoneal neoplasms. Those findings might provide important assessment to predict peritoneal neoplasms patients' immunotherapy responses.
程序性死亡受体-1(PD-1)和 T 细胞免疫球蛋白和粘蛋白结构域 3(Tim-3)可作为评估患者接受腹腔肿瘤治疗效果的生物标志物。在本研究中,我们探索了外周血中 PD-1 和 Tim-3 的差异百分比,以研究其是否与腹腔肿瘤患者的原发部位和病理类型相关。我们还研究了 PD-1 和 Tim-3 在循环淋巴细胞、CD3+T 细胞、CD3+CD4+T 细胞和 CD3+CD8+T 细胞上的频率,以研究其是否与腹腔肿瘤患者的无进展生存期(PFS)相关。
招募了 115 例腹腔肿瘤患者,采用多色流式细胞术分析循环淋巴细胞、CD3+T 细胞、CD3+CD4+T 细胞和 CD3+CD8+T 细胞上 PD-1 和 Tim-3 受体的百分比。根据肿瘤是否有原发灶且局限于腹腔肿瘤,将腹腔肿瘤患者分为原发性和继发性两组。然后根据肿瘤的病理类型(腺癌、间皮瘤和假性黏液瘤)将所有患者重新分组。将继发性腹腔肿瘤组分为不同的原发部位组(结肠、胃、妇科)。本研究还纳入了 38 例正常志愿者。采用流式细胞术检测上述标志物,以发现与正常组相比,外周血中腹腔肿瘤患者的差异水平。
与正常对照组相比,腹腔肿瘤组的 CD4+T 淋巴细胞、CD8+T 淋巴细胞、CD45+PD-1+淋巴细胞、CD3+PD-1+T 细胞、CD3+CD4+PD-1+T 细胞、CD3+CD8+PD-1+T 细胞和 CD45+Tim-3+淋巴细胞百分比更高(p 值分别为 0.004、0.047、0.046、0.044、0.014、0.038 和 0.017)。与原发性腹腔肿瘤组相比,继发性腹腔肿瘤组的 CD45+PD-1+淋巴细胞、CD3+PD-1+T 细胞和 CD3+CD4+PD-1+T 细胞百分比更高(p 值分别为 0.010、0.044 和 0.040),而 PD-1 在继发性组中与原发部位无关(P>0.05)。原发性腹腔肿瘤组与继发性组的 Tim-3 无统计学差异(p>0.05),但 CD45+Tim-3+%淋巴细胞、CD3+Tim-3+%T 细胞和 CD3+CD4+Tim-3+%T 细胞与不同的继发性腹腔肿瘤部位相关(p<0.05)。在不同的病理类型组中,与间皮瘤组相比,腺癌组的 CD45+PD-1+淋巴细胞和 CD3+PD-1+T 细胞百分比更高(p=0.048、p=0.045)。外周血中 CD45+PD-1+淋巴细胞和 CD3+PD-1+T 细胞的频率与 PFS 相关。
我们的工作揭示了外周 PD-1 和 Tim-3 百分比与腹腔肿瘤的原发部位和病理类型相关。这些发现可能为预测腹腔肿瘤患者的免疫治疗反应提供重要评估。